A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
OBJECTIVES:
Primary
- To screen for an indication that the addition of vandetanib to chemoradiotherapy may
prolong disease-free survival as compared to a combination of chemoradiotherapy in
patients with resected, high-risk stage III or IV head and neck squamous cell
carcinoma.
Secondary
- To determine whether this treatment regimen can be delivered safely and successfully
following surgical resection for advanced head and neck cancer.
- To estimate the locoregional progression, distant metastasis, and overall survival
rates for patients treated with this regimen.
- To examine the distribution of selected biomarkers that may include but are not limited
to EGFR (epidermal growth factor receptor, total and phosphorylated), E-cadherin, pMAPK
(phosphorylated mitogen-activated protein kinase), pAKT, Stat-3 (signal transducer and
activator of transcription 3), Ki-67, COX-2 (cyclooxygenase 2), and cyclin B1
(G2/mitotic-specific cyclin-B1)expression in this group of patients and to explore the
potential correlation between these markers with the ultimate treatment outcome
OUTLINE: This is a multicenter study. Patients are stratified according to Zubrod
performance status (0 vs 1) and primary site of disease (oral cavity/hypopharynx vs larynx
vs oropharynx, HPV+ (human papillomavirus positive) vs oropharynx, HPV- (human
papillomavirus negative)). Patients are randomized to 1 of 2 arms.
- Arm I: Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive
cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
- Arm II: Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour
once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib
once daily beginning 14 days prior to the start of radiotherapy.
In both arms, treatment continues for 6 weeks in the absence of disease progression or
unacceptable toxicity.
Tissue samples from all patients are collected and reviewed. Tissue from patients with
oropharyngeal carcinoma is analyzed for human papillomavirus.
After completion of study treatment, patients are followed every 3 months for 2 years, every
6 months for 4 years, and then annually thereafter.
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease-free Survival
This study terminated early with 34 subjects accrued out of 170 planned, therefore no analyses were performed.
From randomization to date of failure (local, regional, or distant progression, or death) or last follow-up. Analysis occurs after 78 failures have been reported.
No
David Raben, MD
Principal Investigator
University of Colorado, Denver
United States: Food and Drug Administration
CDR0000599867
NCT00720083
November 2008
August 2011
Name | Location |
---|---|
Roswell Park Cancer Institute | Buffalo, New York 14263 |
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
Mayo Clinic Scottsdale | Scottsdale, Arizona 85259 |
Mayo Clinic - Jacksonville | Jacksonville, Florida 32224 |
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
Barbara Ann Karmanos Cancer Institute | Detroit, Michigan 48201 |
CCOP - Kansas City | Kansas City, Missouri 64131 |
CCOP - Christiana Care Health Services | Wilmington, Delaware 19899 |
Methodist Cancer Center at Methodist Hospital | Indianapolis, Indiana 46202 |
Case Comprehensive Cancer Center | Cleveland, Ohio 44106-5065 |
Medical College of Wisconsin Cancer Center | Milwaukee, Wisconsin 53226 |
Rapid City Regional Hospital | Rapid City, South Dakota 57709 |
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia | Philadelphia, Pennsylvania 19107 |
Cleveland Clinic Taussig Cancer Center | Cleveland, Ohio 44195 |
USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles, California 90033-0804 |
Rebecca and John Moores UCSD Cancer Center | La Jolla, California 92093-0658 |
City of Hope Comprehensive Cancer Center | Duarte, California 91010 |
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center | Kansas City, Kansas 66160-7353 |
Josephine Ford Cancer Center at Henry Ford Hospital | Detroit, Michigan 48202 |
James Graham Brown Cancer Center at University of Louisville | Louisville, Kentucky 40202 |
Lake/University Ireland Cancer Center | Mentor, Ohio 44060 |
Waukesha Memorial Hospital Regional Cancer Center | Waukesha, Wisconsin 53188 |
Winship Cancer Institute of Emory University | Atlanta, Georgia 30322 |
Hollings Cancer Center at Medical University of South Carolina | Charleston, South Carolina 29425 |
St. Vincent Hospital Regional Cancer Center | Green Bay, Wisconsin 54307-3508 |
James P. Wilmot Cancer Center at University of Rochester Medical Center | Rochester, New York 14642 |
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center | Green Bay, Wisconsin 54301-3526 |
Bay Area Cancer Care Center at Bay Area Medical Center | Marinette, Wisconsin 54143 |
David C. Pratt Cancer Center at St. John's Mercy | St. Louis, Missouri 63141 |
University of New Mexico Cancer Center | Albuquerque, New Mexico 87131-5636 |
Oklahoma University Cancer Institute | Oklahoma City, Oklahoma 73104 |
Geisinger Cancer Institute at Geisinger Health | Danville, Pennsylvania 17822-0001 |
M. D. Anderson Cancer Center at University of Texas | Houston, Texas 77030-4009 |
Virginia Commonwealth University Massey Cancer Center | Richmond, Virginia 23298-0037 |
Gundersen Lutheran Center for Cancer and Blood | La Crosse, Wisconsin 54601 |
University of Virginia Cancer Center | Charlottesville, Virginia 22908 |
Fox Chase Cancer Center - Philadelphia | Philadelphia, Pennsylvania 19111-2497 |
Ingalls Cancer Care Center at Ingalls Memorial Hospital | Harvey, Illinois 60426 |
Highland Hospital of Rochester | Rochester, New York 14620 |
North Coast Cancer Care, Incorporated | Sandusky, Ohio 44870 |
Regional Cancer Center at Singing River Hospital | Pascagoula, Mississippi 39581 |
Truman Medical Center - Hospital Hill | Kansas City, Missouri 64108 |
Leo W. Jenkins Cancer Center at ECU Medical School | Greenville, North Carolina 27834 |
Summa Center for Cancer Care at Akron City Hospital | Akron, Ohio 44309-2090 |
Barberton Citizens Hospital | Barberton, Ohio 44203 |
Flower Hospital Cancer Center | Sylvania, Ohio 43560 |
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center | Reading, Pennsylvania 19612-6052 |
York Cancer Center at Apple Hill Medical Center | York, Pennsylvania 17405 |
Schiffler Cancer Center at Wheeling Hospital | Wheeling, West Virginia 26003 |
Radiological Associates of Sacramento Medical Group, Incorporated | Sacramento, California 95815 |
Regional Cancer Center at Oconomowoc Memorial Hospital | Oconomowoc, Wisconsin 53066 |
Cancer Institute at St. John's Hospital | Springfield, Illinois 62701 |
Sentara Cancer Institute at Sentara Norfolk General Hospital | Norfolk, Virginia 23507 |
Veterans Affairs Medical Center - Milwaukee | Milwaukee, Wisconsin 53295 |
Radiation Oncology Associates, PA | Albuquerque, New Mexico 87109 |
Saint John's Cancer Center at Saint John's Medical Center | Anderson, Indiana 46016 |
Renown Institute for Cancer at Renown Regional Medical Center | Reno, Nevada 89502 |
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center | Sleepy Hollow, New York 10591 |
Fox Chase Cancer Center Buckingham | Furlong, Pennsylvania 18925 |
Saint Elizabeth Cancer Institute at Saint Elizabeth Regional Medical Center | Lincoln, Nebraska 68510 |
Charach Cancer Center at Huron Valley - Sinai Hospital | Commerce, Michigan 48382 |
Memorial Sloan-Kettering Cancer Center - Basking Ridge | Basking Ridge, New Jersey 07920 |
Memorial Sloan-Kettering Cancer Center - Rockville Centre | Rockville Centre, New York 11570 |